Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
BORIS JOHNSON: Our desperate fight to save Donny the dying ducklingNew Seattle coach Mike Macdonald takes it all in during first day of Seahawks rookie minicampTwins put Buxton on injured list with inflammation in troublesome knee; antsy Lewis still rehabbingCongressman praises heckling of war protesters, including 1 who made monkey gestures at Black womanFormer New York Giants player Aaron Thomas, who caught 35 touchdown passes, dies at 86Miami Marlins working on trade that would send 2B Luis Arraez to the San Diego PadresStanton and Rizzo help Yankees rally in 9th inning for 2Former security guard Jake Knapp leads the Byron Nelson after 2 roundsCourt appearance for country star Morgan Wallen in chairYellen says threats to democracy risk US economic growth, an indirect jab at Trump
2.7025s , 6605.2265625 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Global Gazette news portal